Atossa Genetics, Inc. to Present at Biotech Showcase 2012
Published: Dec 28, 2011
SEATTLE, WA--(Marketwire - December 27, 2011) -
"This is an exciting time at Atossa as we have recently launched the ForeCYTE Breast Health Test(sm) for breast cancer risk assessment and the ArgusCYTE Breast Health Test(sm), the only circulating breast tumor cell test available today that identifies mRNA expression levels for estrogen receptors, progesterone receptor, and HER-2 antigen in a single blood draw," stated Dr. Quay. "I am pleased to have this opportunity to tell investors about our company, our suite of products and services, and our growth opportunities."
Breast cancer is a disease that typically develops in stages over an approximately eight-year period. Although current mammography procedures can detect cancer already present in the breast, the ForeCYTE Breast Health Test(sm), by testing samples of nipple aspirate fluid collected from the milk ducts and lobules of the breast, can identify pre-cancerous cellular changes that heighten the risk for breast cancer, empowering doctors and their patients to consider measures such as lifestyle changes and medical treatments that may prevent breast cancer from developing or treat breast cancer earlier, if it develops.
About Atossa Genetics, Inc.
Atossa Genetics, Inc. is a privately held health care company based in Seattle, Washington, that provides a comprehensive set of innovative breast health evaluation products and services that provide accurate and actionable results for personalized cancer prevention and breast health. Atossa has established the National Reference Laboratory for Breast Health, a specially equipped, CLIA-registered laboratory located in Seattle that provides comprehensive test results to guide personalized breast cancer prevention and treatment solutions. Patients, health care providers, investors and others seeking information on Atossa and its products and services should visit www.atossagenetics.com. For information on the ForeCYTE Breast Health Test(sm) or the ArgusCYTE Breast Health Test(sm), please visit http://nrlbh.com/testing-services/risk-assessment.php or call or 800-351-3902.
Steven C. Quay, M.D., Ph.D., FCAP (Corporate)
Chairman, President and CEO of Atossa Genetics and Director of the National Reference Laboratory for Breast Health
Matthew D. Haines (Investors and Media)
MBS Value Partners